Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Managing metastatic bone disease: three case studies.

Robert Coleman1, Axel Heidenreich, Richard Bell

  • 1Yorkshire Cancer Research Academic Unit of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, Sheffield, UK. R.E.Coleman@Sheffield.ac.uk

Seminars in Oncology
|October 19, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aktuelle Urologie·2026
Same author

Diagnostic performance of the microRNA-371a assay in small testicular masses: a real-world cohort study.

BJU international·2026
Same author

[From limited options to individualized strategies: advances in the treatment of bladder cancer].

Urologie (Heidelberg, Germany)·2026
Same author

[Critical self-assessment as an instrument to optimize surgical strategies in the management of upper urinary tract urothelial cancer].

Urologie (Heidelberg, Germany)·2026
Same author

<i>NECTIN4</i> Amplification Is a Frequent Event in Central Nervous System Metastases of Urothelial Carcinoma.

European urology open science·2026
Same author

[Multidisciplinary cancer therapy-more important than ever].

Urologie (Heidelberg, Germany)·2026

Metastatic bone disease management strategies are discussed, focusing on the bisphosphonate ibandronate. Case studies demonstrate ibandronate

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Metastatic bone disease presents significant clinical challenges, leading to skeletal complications and reduced quality of life.
  • Effective management strategies are crucial for reducing skeletal morbidity and alleviating symptoms like severe bone pain.

Observation:

  • This article reviews current management approaches for metastatic bone disease.
  • Emphasis is placed on the role of the bisphosphonate ibandronate in treatment.

Findings:

  • Two case histories highlight the long-term efficacy and tolerability of oral ibandronate in metastatic breast cancer.
  • A third case study demonstrates rapid pain relief with high-dose intravenous ibandronate in metastatic prostate cancer.

Implications:

Related Experiment Videos

  • Ibandronate shows promise for managing metastatic bone disease in various cancers.
  • Oral and intravenous formulations offer flexible treatment options for improving patient outcomes and quality of life.